Free Trial
→ ALERT: Drop these 5 stocks before the market opens tomorrow! (From Weiss Ratings) (Ad)tc pixel Free GDTC Stock Alerts

CytoMed Therapeutics (GDTC) Competitors

CytoMed Therapeutics logo
$0.95 -0.05 (-4.91%)
Closing price 03:57 PM Eastern
Extended Trading
$0.92 -0.03 (-2.85%)
As of 07:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

GDTC vs. TELO, SCYX, NBRV, HYPD, and HOWL

Should you be buying CytoMed Therapeutics stock or one of its competitors? The main competitors of CytoMed Therapeutics include Telomir Pharmaceuticals (TELO), SCYNEXIS (SCYX), Nabriva Therapeutics (NBRV), Hyperion DeFi (HYPD), and Werewolf Therapeutics (HOWL). These companies are all part of the "pharmaceutical products" industry.

How does CytoMed Therapeutics compare to Telomir Pharmaceuticals?

Telomir Pharmaceuticals (NASDAQ:TELO) and CytoMed Therapeutics (NASDAQ:GDTC) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, risk, earnings, valuation, institutional ownership and media sentiment.

Telomir Pharmaceuticals has a beta of -0.21, suggesting that its stock price is 121% less volatile than the S&P 500. Comparatively, CytoMed Therapeutics has a beta of -0.18, suggesting that its stock price is 118% less volatile than the S&P 500.

In the previous week, Telomir Pharmaceuticals had 1 more articles in the media than CytoMed Therapeutics. MarketBeat recorded 1 mentions for Telomir Pharmaceuticals and 0 mentions for CytoMed Therapeutics. Telomir Pharmaceuticals' average media sentiment score of 0.00 equaled CytoMed Therapeutics'average media sentiment score.

Company Overall Sentiment
Telomir Pharmaceuticals Neutral
CytoMed Therapeutics Neutral

CytoMed Therapeutics' return on equity of 0.00% beat Telomir Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Telomir PharmaceuticalsN/A -315.26% -259.29%
CytoMed Therapeutics N/A N/A N/A

CytoMed Therapeutics has higher revenue and earnings than Telomir Pharmaceuticals.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Telomir PharmaceuticalsN/AN/A-$10.41M-$0.33N/A
CytoMed Therapeutics$250K44.86-$3.10MN/AN/A

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Telomir Pharmaceuticals
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
CytoMed Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

0.0% of CytoMed Therapeutics shares are held by institutional investors. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

CytoMed Therapeutics beats Telomir Pharmaceuticals on 6 of the 9 factors compared between the two stocks.

How does CytoMed Therapeutics compare to SCYNEXIS?

CytoMed Therapeutics (NASDAQ:GDTC) and SCYNEXIS (NASDAQ:SCYX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, media sentiment, earnings, valuation, institutional ownership, risk and dividends.

CytoMed Therapeutics has a net margin of 0.00% compared to SCYNEXIS's net margin of -41.79%. CytoMed Therapeutics' return on equity of 0.00% beat SCYNEXIS's return on equity.

Company Net Margins Return on Equity Return on Assets
CytoMed TherapeuticsN/A N/A N/A
SCYNEXIS -41.79%-25.52%-19.33%

CytoMed Therapeutics has a beta of -0.18, indicating that its stock price is 118% less volatile than the S&P 500. Comparatively, SCYNEXIS has a beta of 1.12, indicating that its stock price is 12% more volatile than the S&P 500.

CytoMed Therapeutics has higher earnings, but lower revenue than SCYNEXIS.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CytoMed Therapeutics$250K44.86-$3.10MN/AN/A
SCYNEXIS$20.60M2.04-$8.61M-$0.17N/A

SCYNEXIS has a consensus target price of $3.00, suggesting a potential upside of 218.17%. Given SCYNEXIS's stronger consensus rating and higher possible upside, analysts plainly believe SCYNEXIS is more favorable than CytoMed Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
CytoMed Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
SCYNEXIS
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

In the previous week, SCYNEXIS had 8 more articles in the media than CytoMed Therapeutics. MarketBeat recorded 8 mentions for SCYNEXIS and 0 mentions for CytoMed Therapeutics. CytoMed Therapeutics' average media sentiment score of 0.00 equaled SCYNEXIS'saverage media sentiment score.

Company Overall Sentiment
CytoMed Therapeutics Neutral
SCYNEXIS Neutral

0.0% of CytoMed Therapeutics shares are owned by institutional investors. Comparatively, 54.4% of SCYNEXIS shares are owned by institutional investors. 4.9% of SCYNEXIS shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

SCYNEXIS beats CytoMed Therapeutics on 8 of the 13 factors compared between the two stocks.

How does CytoMed Therapeutics compare to Nabriva Therapeutics?

CytoMed Therapeutics (NASDAQ:GDTC) and Nabriva Therapeutics (NASDAQ:NBRV) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, media sentiment, earnings, valuation, institutional ownership, risk and dividends.

In the previous week, CytoMed Therapeutics' average media sentiment score of 0.00 equaled Nabriva Therapeutics'average media sentiment score.

Company Overall Sentiment
CytoMed Therapeutics Neutral
Nabriva Therapeutics Neutral

CytoMed Therapeutics has a beta of -0.18, indicating that its stock price is 118% less volatile than the S&P 500. Comparatively, Nabriva Therapeutics has a beta of 1.53, indicating that its stock price is 53% more volatile than the S&P 500.

CytoMed Therapeutics has a net margin of 0.00% compared to Nabriva Therapeutics' net margin of -148.11%. CytoMed Therapeutics' return on equity of 0.00% beat Nabriva Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
CytoMed TherapeuticsN/A N/A N/A
Nabriva Therapeutics -148.11%-365.53%-135.81%

CytoMed Therapeutics has higher earnings, but lower revenue than Nabriva Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CytoMed Therapeutics$250K44.86-$3.10MN/AN/A
Nabriva Therapeutics$35.59M0.00-$57.19M-$19.20N/A

0.0% of CytoMed Therapeutics shares are owned by institutional investors. Comparatively, 0.3% of Nabriva Therapeutics shares are owned by institutional investors. 1.6% of Nabriva Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Given Nabriva Therapeutics' higher possible upside, analysts plainly believe Nabriva Therapeutics is more favorable than CytoMed Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
CytoMed Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Nabriva Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Summary

CytoMed Therapeutics and Nabriva Therapeutics tied by winning 5 of the 10 factors compared between the two stocks.

How does CytoMed Therapeutics compare to Hyperion DeFi?

CytoMed Therapeutics (NASDAQ:GDTC) and Hyperion DeFi (NASDAQ:HYPD) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, valuation, analyst recommendations, media sentiment, earnings, risk and institutional ownership.

In the previous week, Hyperion DeFi had 4 more articles in the media than CytoMed Therapeutics. MarketBeat recorded 4 mentions for Hyperion DeFi and 0 mentions for CytoMed Therapeutics. Hyperion DeFi's average media sentiment score of 0.66 beat CytoMed Therapeutics' score of 0.00 indicating that Hyperion DeFi is being referred to more favorably in the news media.

Company Overall Sentiment
CytoMed Therapeutics Neutral
Hyperion DeFi Positive

CytoMed Therapeutics has a beta of -0.18, indicating that its share price is 118% less volatile than the S&P 500. Comparatively, Hyperion DeFi has a beta of 2.57, indicating that its share price is 157% more volatile than the S&P 500.

CytoMed Therapeutics' return on equity of 0.00% beat Hyperion DeFi's return on equity.

Company Net Margins Return on Equity Return on Assets
CytoMed TherapeuticsN/A N/A N/A
Hyperion DeFi N/A -129.97%-92.39%

CytoMed Therapeutics has higher earnings, but lower revenue than Hyperion DeFi.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CytoMed Therapeutics$250K44.86-$3.10MN/AN/A
Hyperion DeFi$810K65.67-$45.31M-$11.80N/A

0.0% of CytoMed Therapeutics shares are held by institutional investors. Comparatively, 25.8% of Hyperion DeFi shares are held by institutional investors. 10.9% of Hyperion DeFi shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Hyperion DeFi has a consensus target price of $5.88, suggesting a potential upside of 25.80%. Given Hyperion DeFi's stronger consensus rating and higher probable upside, analysts clearly believe Hyperion DeFi is more favorable than CytoMed Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
CytoMed Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Hyperion DeFi
2 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
1 Strong Buy rating(s)
2.25

Summary

Hyperion DeFi beats CytoMed Therapeutics on 11 of the 14 factors compared between the two stocks.

How does CytoMed Therapeutics compare to Werewolf Therapeutics?

Werewolf Therapeutics (NASDAQ:HOWL) and CytoMed Therapeutics (NASDAQ:GDTC) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, media sentiment, institutional ownership, risk, dividends, valuation and earnings.

CytoMed Therapeutics' return on equity of 0.00% beat Werewolf Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Werewolf TherapeuticsN/A -158.82% -69.75%
CytoMed Therapeutics N/A N/A N/A

Werewolf Therapeutics has a beta of 0.41, indicating that its stock price is 59% less volatile than the S&P 500. Comparatively, CytoMed Therapeutics has a beta of -0.18, indicating that its stock price is 118% less volatile than the S&P 500.

64.8% of Werewolf Therapeutics shares are owned by institutional investors. Comparatively, 0.0% of CytoMed Therapeutics shares are owned by institutional investors. 23.6% of Werewolf Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Werewolf Therapeutics had 9 more articles in the media than CytoMed Therapeutics. MarketBeat recorded 9 mentions for Werewolf Therapeutics and 0 mentions for CytoMed Therapeutics. CytoMed Therapeutics' average media sentiment score of 0.00 beat Werewolf Therapeutics' score of -0.71 indicating that CytoMed Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Werewolf Therapeutics Negative
CytoMed Therapeutics Neutral

Werewolf Therapeutics currently has a consensus target price of $3.75, suggesting a potential upside of 459.95%. Given Werewolf Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Werewolf Therapeutics is more favorable than CytoMed Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Werewolf Therapeutics
1 Sell rating(s)
4 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.14
CytoMed Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

CytoMed Therapeutics has lower revenue, but higher earnings than Werewolf Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Werewolf Therapeutics$1.88M17.31-$60.82M-$1.36N/A
CytoMed Therapeutics$250K44.86-$3.10MN/AN/A

Summary

Werewolf Therapeutics beats CytoMed Therapeutics on 8 of the 13 factors compared between the two stocks.

Get CytoMed Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for GDTC and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GDTC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

GDTC vs. The Competition

Export
MetricCytoMed TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$11.80M$3.39B$6.24B$11.86B
Dividend YieldN/A2.20%2.73%5.21%
P/E RatioN/A38.8529.0428.48
Price / Sales44.86157.28477.1060.43
Price / CashN/A57.8827.6236.52
Price / Book2.117.039.676.67
Net Income-$3.10M$23.62M$3.55B$332.64M
7 Day Performance0.42%3.67%1.70%2.01%
1 Month Performance-0.94%7.17%5.62%9.19%
1 Year Performance-60.75%67.04%34.42%39.59%

CytoMed Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
GDTC
CytoMed Therapeutics
N/A$0.95
-4.9%		N/AN/A$11.80M$250KN/AN/A
TELO
Telomir Pharmaceuticals
N/A$1.38
+0.7%		N/AN/A$47.10MN/AN/A1
SCYX
SCYNEXIS
1.9745 of 5 stars		$1.05
+1.9%		$3.00
+185.7%		N/A$46M$20.60MN/A60
NBRV
Nabriva Therapeutics
N/AN/AN/AN/A$45.46M$35.59MN/A70
HYPD
Hyperion DeFi
2.9441 of 5 stars		$3.93
-1.3%		$5.88
+49.5%		N/A$45.34M$810KN/A40

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:GDTC) was last updated on 5/5/2026 by MarketBeat.com Staff.
From Our Partners
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
The $1.75T "Backdoor" ticker (NOT Starlink)
When the SpaceX IPO launches, most investors will already be too late. The real opportunity isn't the IPO itse...
Behind the Markets | Sponsoredtc pixel
Sell 99% of Your Stocks, Do THIS Instead…
Millionaire Trader Exposes: "The Single Stock Income Plan" With over 6,000 stocks on the market to choose ...
The Oxford Club | Sponsoredtc pixel
Trade this between 9:30 and 10:45 am EST
The first 75 minutes of the trading day may be the most overlooked window for consistent opportunities.If you ...
Base Camp Trading | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Elon Unveils AI Passive Income Stream for Millions of Americans
During Tesla's last earnings call, Elon Musk outlined a new AI-driven approach he says could generate $30,000-...
InvestorPlace | Sponsoredtc pixel